MATTERHORN: Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

by biblioteca on 27 de juny de 2022 with No hi ha comentaris

Janjigian, Y. Y., Van Cutsem, E., Muro, K., Wainberg, Z., Al-Batran, S. -., Hyung, W. J., . . . Tabernero, J. (2022). MATTERHORN: Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncology, 18(20), 2465-2473. https://doi.org/10.2217/fon-2022-0093